N/A N=550 Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening
Colorectal Neoplasms
Primary: Colorectal Cancer (CRC) Screening Rate. — 40.1; 40.2; 19.3 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=700 Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
Opioid-Induced Constipation (OIC)
Primary: Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12 — 81; 92; 68 Number of patients — p=0.202
Phase 3 N=236 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Pulmonary Fibrosis
Primary: Overall Change in Forced Vital Capacity — -0.18; -0.19 liters
Phase 2 N=53 Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 3.1; 1.9 months
Phase 2 N=75 A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
Parkinson's Disease
Primary: Number of Participants With Any TEAE — 7; 18; 8; 32 Participants
N/A N=20 Influence of Cytochrome CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Ambrisentan
Drug Interactions
Primary: AUC of Ambrisentan — 3670; 3520; 2790 h*ng/ml
N/A N=387 Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
HIV Infections
Primary: Number of Patients Reporting Non-serious Adverse Events, Serious Adverse Events, and Non-serious and Serious Adverse Events Leading to Treatment Discontinuation — 0; 4…
Phase 4 N=25 A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies
Influenza · Common Cold
Primary: Time to Reach Plasma Paracetamol Concentration of 0.25 μg/mL (Microgram Per Milliliter) — 4.59; 23.14 minutes — p=0.0004
Phase 2 N=150 Study of Gardasil in Mid-Adult Males (MAM)
Human Papillomavirus
Primary: Percentage of Participants Seropositive at Month 7 — 100; 100; 100; 100 percentage of participants
Phase 2 N=14 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Glomerulonephritis, Membranous
Primary: Change From Baseline in Proteinuria Levels at Week 28 — 0.7552 Ratio
Phase 2 N=53 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Uveal Melanoma · Liver Metastases
Primary: Response of Liver Metastases — 0; 0; 5; 3 participants
N/A N=227 A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal
Tooth Stain
Primary: Lobene Stain Index Composite Score at Day 15 — 2.568; 1.909; 1.575 units on a scale — p=<0.001
N/A N=4,681 Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)
Ankylosing Spondylitis
Primary: Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score — 5.5; -2.0; -2.1; -2.2 BASDAI score
N/A N=121 Mood and Diabetes Empowerment & Improvement Training
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c at 6 Months — -0.7; -1.6 percentage of glycated hemoglobin
Phase 4 N=456 Evaluation of the Human Rotavirus Vaccine at Varying Schedules and Doses in Rural Ghana
Rotavirus Gastroenteritis
Primary: Immunoglobulin A (IgA) Seroconversion: 6 & 10 Week vs. 6, 10, & 14 Week Vaccination Schedules — 28.9; 43.4 percentage of participants — p=0.014